BAJAJ BROKING
Cipla's Medispray unit in Goa received one US FDA Form 483 observation after a detailed inspection. The company is addressing the issue within FDA timelines. Cipla share price closed at ₹1,445.90 on January 20, 2025, marginally up by 0.24%.
Pharmaceutical giant Cipla announced that the US FDA inspected its subsidiary Medispray Laboratories in Kundaim, Goa, between 14-20 January 2025. Following the inspection, the facility received a single observation documented in Form 483. Cipla assured stakeholders of its commitment to addressing the observation promptly within the stipulated timeline, ensuring strict adherence to Good Manufacturing Practices (GMP).
Also read: RBI Forms External Advisory Committee for Universal and Small Finance Banks
Facility Location: Medispray Laboratories, Kundaim, Goa
Inspection Period: 14-20 January 2025
Observation: One Form 483 issued by the US FDA
Action Plan: Cipla will respond to the FDA within 15 days
Cipla Share Price: Closed at ₹1,445.90 on January 20, 2025
Also read: TCS Opens AI-Powered Delivery Centre in France for Aerospace
Form 483, issued by the US FDA, lists observations made during inspections regarding potential deviations from GMP. It is not a final determination but serves as a preliminary communication. Companies receiving Form 483 have 15 days to submit corrective actions to the FDA, showcasing their compliance plan.
Inspection Details | Information |
Facility Name | Medispray Laboratories |
Location | Kundaim, Goa |
Inspection Duration | 14-20 January 2025 |
Observations (Form 483) | 1 |
On the day of the announcement, Cipla share price ended at ₹1,445.90, marking a 0.24% increase. Investors are monitoring the situation as Cipla’s commitment to GMP compliance and prompt issue resolution reflects its operational reliability.
Cipla emphasised its proactive approach, stating that the observation would be addressed comprehensively within the stipulated timeline. This reflects Cipla’s strong compliance framework and its dedication to maintaining FDA standards.
The US FDA Form 483 observation highlights areas requiring attention but does not indicate significant non-compliance. Cipla’s transparent communication and swift corrective measures underscore its focus on regulatory adherence, instilling confidence in stakeholders. With a resilient operational framework, Cipla remains poised to resolve the issue efficiently.
Also read: Reliance Power Appoints Neeraj Parakh as CEO for Three Years
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading